Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 2
1978 1
1980 1
1981 1
1982 1
1983 2
1984 1
1985 2
1986 2
1987 1
1988 1
1989 2
1990 2
1991 2
1992 2
1993 5
1994 7
1995 2
1996 5
1997 5
1998 2
1999 3
2000 6
2001 8
2002 7
2003 7
2004 7
2005 5
2006 5
2007 7
2008 5
2009 12
2010 13
2011 19
2012 19
2013 22
2014 22
2015 22
2016 22
2017 35
2018 25
2019 23
2020 25
2021 28
2022 23
2023 19
2024 13

Text availability

Article attribute

Article type

Publication date

Search Results

406 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Metastatic Malignant Neoplasm in the Anus"
Page 1
Preoperative Treatment of Locally Advanced Rectal Cancer.
Schrag D, Shi Q, Weiser MR, Gollub MJ, Saltz LB, Musher BL, Goldberg J, Al Baghdadi T, Goodman KA, McWilliams RR, Farma JM, George TJ, Kennecke HF, Shergill A, Montemurro M, Nelson GD, Colgrove B, Gordon V, Venook AP, O'Reilly EM, Meyerhardt JA, Dueck AC, Basch E, Chang GJ, Mamon HJ. Schrag D, et al. N Engl J Med. 2023 Jul 27;389(4):322-334. doi: 10.1056/NEJMoa2303269. Epub 2023 Jun 4. N Engl J Med. 2023. PMID: 37272534 Free PMC article. Clinical Trial.
METHODS: We conducted a multicenter, unblinded, noninferiority, randomized trial of neoadjuvant FOLFOX (with chemoradiotherapy given only if the primary tumor decreased in size by <20% or if FOLFOX was discontinued because of side effects) as compared with chemor …
METHODS: We conducted a multicenter, unblinded, noninferiority, randomized trial of neoadjuvant FOLFOX (with chemoradiotherapy …
Human papillomavirus and cervical cancer.
Crosbie EJ, Einstein MH, Franceschi S, Kitchener HC. Crosbie EJ, et al. Lancet. 2013 Sep 7;382(9895):889-99. doi: 10.1016/S0140-6736(13)60022-7. Epub 2013 Apr 23. Lancet. 2013. PMID: 23618600
Most human papillomavirus infection is harmless and clears spontaneously but persistent infection with high-risk human papillomavirus (especially type 16) can cause cancer of the cervix, vulva, vagina, anus, penis, and oropharynx. The virus exclusively infects epithelium a …
Most human papillomavirus infection is harmless and clears spontaneously but persistent infection with high-risk human papillomavirus (espec …
Anal Cancer: The Past, Present and Future.
Gondal TA, Chaudhary N, Bajwa H, Rauf A, Le D, Ahmed S. Gondal TA, et al. Curr Oncol. 2023 Mar 11;30(3):3232-3250. doi: 10.3390/curroncol30030246. Curr Oncol. 2023. PMID: 36975459 Free PMC article. Review.
Among anal cancer, squamous cell cancer is the most common malignancy. The incidence of all stages of anal squamous cell cancer has been increasing. Human papillomavirus infection and immunosuppression are major risk factors for anal cancer. ...
Among anal cancer, squamous cell cancer is the most common malignancy. The incidence of all stages of anal squamous cell cance …
Meta-analysis of neoadjuvant immunotherapy for non-metastatic colorectal cancer.
Zhou L, Yang XQ, Zhao GY, Wang FJ, Liu X. Zhou L, et al. Front Immunol. 2023 Jan 27;14:1044353. doi: 10.3389/fimmu.2023.1044353. eCollection 2023. Front Immunol. 2023. PMID: 36776899 Free PMC article.
BACKGROUND: Immunotherapy has been approved for the treatment of metastatic colorectal cancer. The efficacy and safety of neoadjuvant immunotherapy for the treatment of non-metastatic colorectal cancer remains unclear. We tried to explore clinical effect of n …
BACKGROUND: Immunotherapy has been approved for the treatment of metastatic colorectal cancer. The efficacy and safety of neoadjuvant …
Immunotherapy in Anal Cancer.
Phuong L, Rajdev L. Phuong L, et al. Curr Oncol Rep. 2020 Jul 11;22(9):94. doi: 10.1007/s11912-020-00946-3. Curr Oncol Rep. 2020. PMID: 32651760 Review.
PURPOSE OF REVIEW: Standard treatment for early-stage squamous cell cancer of the anal canal (SCCA) includes concurrent chemotherapy and radiation to achieve curative intent. ...So far, single-agent monotherapy with either nivolumab or pembrolizumab has shown durabl …
PURPOSE OF REVIEW: Standard treatment for early-stage squamous cell cancer of the anal canal (SCCA) includes concurrent chemot …
International Rare Cancers Initiative Multicenter Randomized Phase II Trial of Cisplatin and Fluorouracil Versus Carboplatin and Paclitaxel in Advanced Anal Cancer: InterAAct.
Rao S, Sclafani F, Eng C, Adams RA, Guren MG, Sebag-Montefiore D, Benson A, Bryant A, Peckitt C, Segelov E, Roy A, Seymour MT, Welch J, Saunders MP, Muirhead R, O'Dwyer P, Bridgewater J, Bhide S, Glynne-Jones R, Arnold D, Cunningham D. Rao S, et al. J Clin Oncol. 2020 Aug 1;38(22):2510-2518. doi: 10.1200/JCO.19.03266. Epub 2020 Jun 12. J Clin Oncol. 2020. PMID: 32530769 Free PMC article. Clinical Trial.
PURPOSE: To compare cisplatin plus fluorouracil (FU) versus carboplatin plus paclitaxel in chemotherapy-naive advanced anal cancer to establish the optimal regimen. PATIENTS AND METHODS: Patients who had not received systemic therapy for advanced anal cancer were …
PURPOSE: To compare cisplatin plus fluorouracil (FU) versus carboplatin plus paclitaxel in chemotherapy-naive advanced anal cancer to …
Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study.
Morris VK, Salem ME, Nimeiri H, Iqbal S, Singh P, Ciombor K, Polite B, Deming D, Chan E, Wade JL, Xiao L, Bekaii-Saab T, Vence L, Blando J, Mahvash A, Foo WC, Ohaji C, Pasia M, Bland G, Ohinata A, Rogers J, Mehdizadeh A, Banks K, Lanman R, Wolff RA, Streicher H, Allison J, Sharma P, Eng C. Morris VK, et al. Lancet Oncol. 2017 Apr;18(4):446-453. doi: 10.1016/S1470-2045(17)30104-3. Epub 2017 Feb 18. Lancet Oncol. 2017. PMID: 28223062 Free PMC article. Clinical Trial.
BACKGROUND: Squamous cell carcinoma of the anal canal (SCCA) is a rare malignancy associated with infection by human papillomavirus (HPV). No consensus treatment approach exists for the treatment of metastatic disease. Because intratumoral HPV oncoproteins up …
BACKGROUND: Squamous cell carcinoma of the anal canal (SCCA) is a rare malignancy associated with infection by human papilloma …
Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial.
Ajani JA, Winter KA, Gunderson LL, Pedersen J, Benson AB 3rd, Thomas CR Jr, Mayer RJ, Haddock MG, Rich TA, Willett C. Ajani JA, et al. JAMA. 2008 Apr 23;299(16):1914-21. doi: 10.1001/jama.299.16.1914. JAMA. 2008. PMID: 18430910 Clinical Trial.
OBJECTIVE: To compare the efficacy of cisplatin-based (experimental) therapy vs mitomycin-based (standard) therapy in treatment of anal canal carcinoma. DESIGN, SETTING, AND PARTICIPANTS: US Gastrointestinal Intergroup trial RTOG 98-11, a multicenter, phase 3 …
OBJECTIVE: To compare the efficacy of cisplatin-based (experimental) therapy vs mitomycin-based (standard) therapy in treatment of anal …
Use of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: Initial Results From the Pembrolizumab Arm of a Phase 2 Randomized Clinical Trial.
Rahma OE, Yothers G, Hong TS, Russell MM, You YN, Parker W, Jacobs SA, Colangelo LH, Lucas PC, Gollub MJ, Hall WA, Kachnic LA, Vijayvergia N, O'Rourke MA, Faller BA, Valicenti RK, Schefter TE, George S, Kainthla R, Stella PJ, Sigurdson E, Wolmark N, George TJ. Rahma OE, et al. JAMA Oncol. 2021 Aug 1;7(8):1225-1230. doi: 10.1001/jamaoncol.2021.1683. JAMA Oncol. 2021. PMID: 34196693 Free PMC article. Clinical Trial.
DESIGN, SETTING, AND PARTICIPANTS: In this open-label, phase 2, randomized clinical trial (NRG-GI002), patients in academic and private practice settings were enrolled. Patients with stage II/III LARC with distal location (cT3-4 5 cm from anal verge, a …
DESIGN, SETTING, AND PARTICIPANTS: In this open-label, phase 2, randomized clinical trial (NRG-GI002), patients in acad …
406 results